Neuland Laboratories Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Neuland Laboratories share price Rs 20,890.00 (9 October 2026). Base target Rs 23,143, bull Rs 28,063, downside risk Rs 16,811. PE 54.16. 52W range Rs 11,500.00 to Rs 24,225.00.

Investors weighing a Neuland Laboratories target price for 2027 should start with where the stock sits today. At Rs 20,890.00 on 9 October 2026, it is 13.8% below its 52-week high of Rs 24,225.00 and 81.7% above its 52-week low of Rs 11,500.00. That range spans 111% from low to high, so the entry point matters as much as the Neuland Laboratories price forecast itself.

This article builds the Neuland Laboratories share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 23,143 base case and the Rs 28,063 bull case were reached, along with a downside risk level of Rs 16,811.

Click Here – Get Free Investment Predictions

Neuland Laboratories Stock Analysis: Company Overview and Key Stats

Neuland Laboratories (NSE: NEULANDLAB) has a market capitalisation of Rs 26,961 crore. In FY26 it reported revenue of Rs 2,053 crore and net profit of Rs 364 crore. The table collects the figures the Neuland Laboratories share price target is built on.

Metric	Value
Company	Neuland Laboratories
NSE Ticker	NEULANDLAB
CMP (9 October 2026)	Rs 20,890.00
52-Week High	Rs 24,225.00
52-Week Low	Rs 11,500.00
Market Cap	Rs 26,961 crore
PE Ratio (TTM)	54.16
Industry PE	37.59
Price to Book	14.39
Return on Equity	19.42%
Debt to Equity	0.16
EPS (TTM)	Rs 387.98
Dividend Yield	0.16%
12-Month Base Target	Rs 23,143
Bull Case	Rs 28,063
Downside Risk Level (not a target)	Rs 16,811

Why Is Neuland Laboratories Share Price Target Set at Rs 23,143 for 2027?

The base-case Neuland Laboratories stock target of Rs 23,143 applies a PE multiple of 54.16 to a forward EPS estimate of Rs 427.31. That EPS assumes 10.1% yearly growth, the pace from FY24 to FY26, and puts the target 10.8% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Neuland Laboratories Target Price: Five Years of Results

Neuland Laboratories grew revenue from Rs 953.15 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew faster, from Rs 63.82 crore to Rs 364 crore (54.5% a year), which shows margin gains did part of the work and not just higher sales.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	953.15	63.82	49.74	5.00
FY23	1,200.95	163.52	127.45	10.00
FY24	1,571.12	300.08	233.89	14.00
FY25	1,497.35	260.11	202.74	12.00
FY26	2,053.15	364.00	283.71	34.00

FY26 revenue growth was 37.1%, faster than the four-year average of 21.1%, and net profit moved up 39.9%. EPS rose from Rs 233.89 in FY24 to Rs 283.71 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Neuland Laboratories converted 17.7% of FY26 revenue into net profit, against 17.4% in FY25, within a five-year range of 6.7% to 19.1%. EBITDA margin was 29.5% in FY26 versus 28.1% in FY25.

In the June 2026 quarter, revenue was Rs 650.07 crore, up 116.3% from the same quarter a year earlier, while net profit of Rs 147.67 crore was up 962.4%. EBITDA came in at Rs 231.38 crore, up 446.4% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.16, and shareholders’ equity grew from Rs 840.50 crore in FY22 to Rs 1,874 crore in FY26. Operating cash flow in FY26 was Rs 346.68 crore against capital expenditure of Rs 397.13 crore, leaving negative free cash flow of Rs 50.45 crore. In FY25 free cash flow was Rs 110.94 crore, so cash generation has not been steady year to year.

Valuation Check for the Neuland Laboratories Stock Target: PE, Price to Book and ROE

At a PE of 54.16 against an industry PE of 37.59, Neuland Laboratories trades at a premium to its industry. Price to book is 14.39 on a book value of Rs 1,460.31 per share, and return on equity is 19.42%. A PE of 54.16 equals an earnings yield of 1.8%, and the FY26 dividend of Rs 34.00 per share gives a yield of 0.16%.

Shareholding Pattern and Institutional Holding

Promoters held 32.62% of Neuland Laboratories in June 2026, and promoter holding has stayed near 32.62% since June 2025. Foreign institutional investors (FII) held 21.08% and domestic institutions (DII) held 16.51%, which puts total institutional holding at 37.59%. FII holding fell from 21.69% in June 2025 to 21.08% in June 2026. Public shareholders own the remaining 29.79%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Neuland Laboratories Share Price Targets for the Short Term and 12 Months

Short Term Neuland Laboratories Stock Target Levels: Technical Setup

At Rs 20,890.00 on 9 October 2026, Neuland Laboratories trades below its 50-day simple moving average of Rs 22,322.08 and above its 200-day exponential moving average of Rs 18,363.52. The 14-day RSI reads 17.8, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 22,322.08 (50-day simple moving average) and the nearest support is Rs 18,363.52 (200-day exponential moving average). A sustained move above Rs 22,322.08 would improve the short-term setup, while a close below Rs 18,363.52 would shift attention to the next support.

12 Month Neuland Laboratories Target Price for 2027

The 12-month target for Neuland Laboratories is Rs 23,143: forward EPS of Rs 427.31 at a PE of 54.16. That is 10.8% above Rs 20,890.00. It would still leave the stock 4.5% below its 52-week high of Rs 24,225.00.

How EPS Growth and PE Multiple Change the Neuland Laboratories Target Price

EPS Growth	PE 43.33	PE 54.16	PE 62.28
0.0% (EPS Rs 387.98)	Rs 16,811	Rs 21,013	Rs 24,163
10.1% (EPS Rs 427.31)	Rs 18,515	Rs 23,143	Rs 26,613
16.1% (EPS Rs 450.59)	Rs 19,524	Rs 24,404	Rs 28,063

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Neuland Laboratories price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Neuland Laboratories Stock Target in 2027

Bull Case Rs 28,063

The bull case Neuland Laboratories price target needs EPS growth of 16.1%, which lifts forward EPS to Rs 450.59, and a PE multiple that rises 15% to 62.28. That gives Rs 28,063, 34.3% above the current price and above the 52-week high of Rs 24,225.00, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 16,811

The downside risk level is not a target. It assumes EPS stays flat at Rs 387.98 and the PE falls 20% to 43.33. That gives Rs 16,811, 19.5% below the current price and above the 52-week low of Rs 11,500.00.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	16.1%	62.28	Rs 28,063	+34.3%
Base Case	10.1%	54.16	Rs 23,143	+10.8%
Downside Risk	0.0%	43.33	Rs 16,811	-19.5%

Key Risks to the Neuland Laboratories Target Price for 2027

Growth Slowdown Risk for the Neuland Laboratories Price Target

Revenue in the June 2026 quarter was up 116.3% year on year, and FY26 revenue growth was 37.1%. If growth slows from here, the EPS estimate behind the Neuland Laboratories stock target will need revising.

Liquidity and Size Risk

Neuland Laboratories has a market capitalisation of Rs 26,961 crore. Institutional holding is 37.59%, and promoters hold 32.62%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.

Valuation and Margin Risk

Net margin was 17.7% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 54.16 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 43.33 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 13.8% below its 52-week high, with an RSI of 17.8 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in Neuland Laboratories

Start with the live price and volume. Any Neuland Laboratories share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 20,890.00 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Neuland Laboratories’ PE, ROE, debt and shareholding in one place.

Check Neuland Laboratories fundamentals on the Univest Screener

Then compare the three Neuland Laboratories target price scenarios with your own view. If you expect EPS growth below 10.1%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Neuland Laboratories live price and get daily stock recommendations.

Conclusion

The Neuland Laboratories share price target for 2027 is Rs 23,143 in the base case, with Rs 28,063 as the bull case. The support for that view is arithmetic you can check: EPS grew 10.1% a year over FY24 to FY26, and the stock trades at a PE of 54.16. The risks are equally concrete, including a stock that sits 13.8% below its 52-week high and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Neuland Laboratories Share Price Target 2027

What is the Neuland Laboratories share price target for 2027?

Ans. The base-case Neuland Laboratories share price target for 2027 is Rs 23,143, with Rs 28,063 as the bull case. The downside risk level, which is not a target, is Rs 16,811. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the Neuland Laboratories share price today?

Ans. As of 9 October 2026, 3:30 PM IST, Neuland Laboratories trades at Rs 20,890.00, down 0.59% on the day. The 52-week range is Rs 11,500.00 to Rs 24,225.00.

Is Neuland Laboratories a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 10.1% a year over FY24 to FY26, but the stock is 13.8% below its 52-week high. Whether Neuland Laboratories fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for Neuland Laboratories shares?

Ans. The bull case target is Rs 28,063, which assumes 16.1% EPS growth and a PE of 62.28. The downside risk level is Rs 16,811, which assumes flat EPS and a PE of 43.33. It marks a risk, not a target.

What are the main risks to the Neuland Laboratories price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 26,961 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of Neuland Laboratories and how does it compare with the industry?

Ans. The PE ratio of Neuland Laboratories is 54.16 against an industry PE of 37.59. Price to book is 14.39 and return on equity is 19.42%. The base case in the Neuland Laboratories price target holds this PE constant.

Who owns Neuland Laboratories, and what is the promoter holding?

Ans. Promoters held 32.62% of Neuland Laboratories in June 2026. FII held 21.08%, DII held 16.51% and the public held 29.79%.

What were Neuland Laboratories’ latest quarterly results?

Ans. In the June 2026 quarter, Neuland Laboratories reported revenue of Rs 650.07 crore (up 116.3% year on year) and net profit of Rs 147.67 crore (up 962.4%).